我武生物(300357) - 2024 Q3 - 季度财报

I. Key Financial Data Key Accounting Data and Financial Indicators The company reported Q1-Q3 2024 operating revenue of RMB 730 million (+8.38% YoY) and net profit of RMB 272 million (+0.78% YoY), with total assets reaching RMB 2.701 billion 2024 Q1-Q3 and Q3 Key Financial Data | Indicator | Year-to-Date (RMB) | YoY Change (Year-to-Date) | Current Period (RMB) | YoY Change (Current Period) | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 730,238,304.07 | 8.38% | 300,981,256.26 | 4.69% | | Net Profit Attributable to Shareholders | 272,253,993.52 | 0.78% | 123,022,999.50 | 1.22% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 263,748,769.90 | 0.31% | 122,244,581.77 | 1.50% | | Net Cash Flow from Operating Activities | 160,173,375.99 | -36.27% | -- | -- | | Basic EPS (RMB/share) | 0.5200 | 0.78% | 0.2350 | 1.25% | 2024 Q3 End Key Balance Sheet Data | Indicator | As of Report Period End (RMB) | As of Previous Year-End (RMB) | Change from Previous Year-End | | :--- | :--- | :--- | :--- | | Total Assets | 2,701,045,459.61 | 2,562,166,715.87 | 5.42% | | Shareholders' Equity Attributable to the Parent Company | 2,360,488,987.56 | 2,185,099,454.42 | 8.03% | Non-Recurring Gains and Losses Items and Amounts Non-recurring gains and losses totaled RMB 8.5052 million in Q1-Q3 2024, mainly from government grants and entrusted investments, with some recurring items reclassified 2024 Q1-Q3 Non-Recurring Gains and Losses Items | Item | Year-to-Date Amount (RMB) | | :--- | :--- | | Gains/Losses on Disposal of Non-Current Assets | 568,926.85 | | Government Grants Recognized in Current Profit/Loss | 10,919,228.53 | | Gains/Losses from Fair Value Changes of Financial Assets/Liabilities | -763,407.78 | | Gains/Losses from Entrusted Investments or Asset Management | 2,497,449.91 | | Other Non-Operating Income and Expenses | -2,878,213.73 | | Total | 8,505,223.62 | - The company classified individual income tax handling fee refunds (RMB 0.135 million) and asset-related government grants (RMB 1.3147 million) as recurring items due to their close relation to normal operations and continuous nature[4] Analysis of Changes in Key Financial Data and Indicators Revenue growth was driven by core product sales, notably Artemisia Annua Pollen Allergen Sublingual Drops (+87.53% YoY), while significant changes occurred in balance sheet and cash flow items 2024 Q1-Q3 Key Product Sales Revenue | Product Name | Sales Revenue (RMB) | YoY Growth | | :--- | :--- | :--- | | Dermatophagoides Farinae Drops | 700,513,594.48 | 7.22% | | Artemisia Annua Pollen Allergen Sublingual Drops | 20,570,536.02 | 87.53% | | Skin Prick Test Diagnostic Kit | 5,690,962.31 | - | - Balance Sheet Key Changes: - Trading financial assets increased by 40.67%, due to the purchase of bank wealth management products[6] - Accounts receivable increased by 60.77%, due to growth in operating revenue[6] - Construction in progress increased by 36.59%, due to increased expenditures for factory construction projects like the stem cell innovation technology and industrialization project[6] - Cash Flow Statement Key Changes: - Net cash flow from operating activities decreased by 36.27%, mainly due to reduced cash received from sales and increased cash paid for other operating activities[6] - Net cash flow from investing activities decreased by 1071.34%, mainly due to reduced cash received from investment recoveries and increased cash paid for investments[6] - Net cash flow from financing activities decreased by 363.33%, mainly due to reduced cash received from subsidiary's absorption of minority shareholder investments and borrowings[6] II. Shareholder Information Total Number of Common Shareholders, Preferred Shareholders with Restored Voting Rights, and Top Ten Shareholders' Holdings The company had 33,867 common shareholders, with the top ten, including controlling shareholder Zhejiang Wuwu Management Consulting Co., Ltd. (38.86%), holding a significant stake Top Ten Shareholders' Holdings | Shareholder Name | Shareholder Nature | Holding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | Zhejiang Wuwu Management Consulting Co., Ltd. | Domestic Non-State-Owned Legal Person | 38.86% | 203,454,131 | | Hu Gengxi | Domestic Natural Person | 8.35% | 43,698,370 | | National Social Security Fund 112 Portfolio | Other | 4.98% | 26,081,102 | | Industrial and Commercial Bank of China - E Fund ChiNext ETF | Other | 1.46% | 7,636,654 | | Chen Jianhui | Domestic Natural Person | 1.37% | 7,194,691 | - The company's controlling shareholder is Zhejiang Wuwu Management Consulting Co., Ltd., and the actual controllers are Mr. Hu Gengxi and Ms. YANNI CHEN (Chen Yanni) couple[8] - Additionally, some shareholders have related party relationships, such as Chen Jianhui and Chen Hongping being siblings, and Chen Hongping and Chen Minzhi being siblings[8] Changes in Restricted Shares No preferred shareholders or restricted share changes occurred, though some top ten shareholders' holdings varied due to securities lending - During the reporting period, the company had no preferred shareholders or changes in restricted shares[10] - Some institutional shareholders, such as "E Fund ChiNext ETF" and "CSI 500 ETF", experienced changes in their period-end shareholdings compared to the beginning of the period due to participation in securities lending transactions[9] III. Other Significant Matters The company advanced its R&D pipeline, with 'Dermatitis Diagnostic Patch 01' entering clinical trials and 'House Dust Mite Film' drug application accepted - In August 2024, the company's "Dermatitis Diagnostic Patch 01" completed its first subject enrollment, officially entering clinical trials[10] - In August 2024, Shanghai Kaiyi Pharmaceutical, an associate company, completed a safety and pharmacodynamics study of "Kuding Saponin A Solution for Inhalation" for moderate to severe COPD patients, and a clinical trial summary report was generated[10] - In September 2024, the company's drug clinical trial application for "House Dust Mite Film" was officially accepted by the National Medical Products Administration[11] IV. Quarterly Financial Statements 1. Consolidated Balance Sheet As of September 30, 2024, total assets reached RMB 2.701 billion (+5.42% YoY), total liabilities decreased by 10.35%, and parent company equity increased by 8.03% Consolidated Balance Sheet Key Items | Item | Period-End Balance (RMB) | Period-Start Balance (RMB) | Change | | :--- | :--- | :--- | :--- | | Total Assets | 2,701,045,459.61 | 2,562,166,715.87 | 5.42% | | Total Liabilities | 231,705,407.38 | 258,460,301.28 | -10.35% | | Total Equity Attributable to Parent Company Shareholders | 2,360,488,987.56 | 2,185,099,454.42 | 8.03% | | Total Shareholders' Equity | 2,469,340,052.23 | 2,303,706,414.59 | 7.19% | 2. Consolidated Income Statement (Year-to-Date as of Report Period End) Q1-Q3 2024 total operating revenue was RMB 730 million (+8.38% YoY), with net profit attributable to parent company shareholders at RMB 272 million (+0.78% YoY) 2024 Q1-Q3 Consolidated Income Statement Key Data | Item | Current Period Amount (RMB) | Prior Period Amount (RMB) | YoY Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 730,238,304.07 | 673,790,861.60 | 8.38% | | Operating Profit | 316,179,068.63 | 300,587,813.26 | 5.19% | | Total Profit | 313,524,164.66 | 301,462,178.69 | 4.00% | | Net Profit Attributable to Parent Company Shareholders | 272,253,993.52 | 270,147,812.94 | 0.78% | | Basic EPS | 0.5200 | 0.5160 | 0.78% | 3. Consolidated Cash Flow Statement (Year-to-Date as of Report Period End) Net cash flow from operating activities decreased by 36.27% to RMB 160 million, while investing and financing cash flows also saw significant negative shifts 2024 Q1-Q3 Consolidated Cash Flow Statement Key Data | Item | Current Period Amount (RMB) | Prior Period Amount (RMB) | Change | | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 160,173,375.99 | 251,344,907.02 | -36.27% | | Net Cash Flow from Investing Activities | -544,564,451.38 | 56,063,321.85 | -1071.34% | | Net Cash Flow from Financing Activities | -120,336,902.70 | -25,972,127.30 | -363.33% | | Net Increase in Cash and Cash Equivalents | -504,730,277.04 | 281,447,920.66 | -279.33% |